"CD52 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB).
| Descriptor ID |
D000074301
|
| MeSH Number(s) |
D12.776.395.550.448.190 D12.776.543.484.500.190 D12.776.543.550.418.190 D23.050.285.022 D23.101.100.943
|
| Concept/Terms |
CD52 Antigen- CD52 Antigen
- CDw52 Antigen
- Campath-1 Antigen
- Campath 1 Antigen
- Campath-1H Antigen
- Campath 1H Antigen
- Lymphocyte Antigen CDw52
- CDw52, Lymphocyte Antigen
- Lymphocyte Antigen CD52
- CD52, Lymphocyte Antigen
- Campath-1 Receptor
- Campath 1 Receptor
- HLA-Bw52 Antigen
- HLA Bw52 Antigen
- HLA-Bw52
- HLA Bw52
- Cambridge Pathology 1 Antigen
- CD52 Protein
|
Below are MeSH descriptors whose meaning is more general than "CD52 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CD52 Antigen".
This graph shows the total number of publications written about "CD52 Antigen" by people in this website by year, and whether "CD52 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD52 Antigen" by people in Profiles.
-
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct; 50(10):1589-96.
-
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 2008 May 15; 68(10):3863-72.
-
The emerging role of alemtuzumab in chronic lymphocytic leukemia. Clin Lymphoma Myeloma. 2005 Sep; 6(2):115-21.
-
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005 Apr; 200(4):505-15; quiz A59-61.
-
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004 Nov; 45(11):2269-73.
-
Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin Oncol. 2002 Feb; 29(1 Suppl 2):75-80.